Abstract:To investigate reversal effects of pantoprazole (PPZ) on multidrug resistance (MDR) in human gastric adenocarcinoma cells in vivo and in vitro. Human gastric adenocarcinoma cell SGC7901 was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics in a humidified 5% CO2 atmosphere at 37 degrees C. Adriamycin (ADR)-resistant cells were cultured with addition of 0.8 mu g/ml of ADR maintaining MDR phenotype. ADR was used to calculate ADR releasing index; CCK-8 Assay was performed to evaluate the cytotoxicity of anti-tumor drugs; BCECF-AM pH-sensitive fluorescent probe was used to measure intracellular pH (pHi) value of cells, whereas pH value of medium was considered as extracellular pH (pHe) value; Western blotting and immunofluorescent staining analyses were employed to determine protein expressions and intracellular distributions of vacuolar H+-ATPases (V-ATPases), mTOR, HIF-1 alpha, P-glycoprotein (P-gp), and multidrug resistant protein 1 (MRP1); SGC7901 and SGC7901/ADR cells were inoculated in athymic nude mice. Thereafter, effects of ADR with or without PPZ pretreatment were compared by determining the tumor size and weight, apoptotic cells in tumor tissues were detected by TUNEL assay. At concentrations greater than 20 mu g/ml, PPZ pretreatment reduced ADR releasing index and significantly enhanced intracellular ADR concentration of SGC7901 (P < 0.01). Similarly, PPZ pretreatment significantly decreased ADR releasing index of SGC7901/ADR dose-dependently (P < 0.01). PPZ pretreatment also decreased cell viabilities of SGG7901 and SGC7901/ADR dose-dependently. After 24-h PPZ pretreatment, administration of chemotherapeutic agents demonstrated maximal cytotoxic effects on SGC7901 and SGC7901/ADR cells (P < 0.05). The resistance index in PPZ pretreatment group was significantly lower than that in non-PPZ pretreatment group (3.71 vs. 14.80). PPZ at concentration >10 mu g/ml significantly decreased pHi in SGC7901 and SGC7901/ADR cells and diminished or reversed transmembrane pH gradient (P< 0.05). PPZ pretreatment also significantly inhibited protein expressions of V-ATPases, mTOR, HIF-1 alpha P-gp, and MRP1, and alter intracellular expressions in parent and ADR-resistant cells (P < 0.05). In vivo experiments further confirmed that PPZ pretreatment could enhance anti-tumor effects of ADR on xenografted tumor of nude mice and also improve the apoptotic index in xenografted tumor tissues. PPZ pretreatment enhances the cytotoxic effects of anti-tumor drugs on SGC7901 and reverse MDR of SGC7901/ADR by downregulating the V-ATPases/mTOR/HIF-1 alpha/P-gp and MRP1 signaling pathway. J. Cell. Biochem. 113: 2474-2487, 2012. (C) 2012 Wiley Periodicals, Inc.

Effects and Mechanisms of Proton Pump Inhibitors As a Novel Chemosensitizer on Human Gastric Adenocarcinoma ( SGC 7901 ) Cells

Pretreatment with Proton Pump Inhibitor Increases Sensitivity of Human Gastric Adenocarcinoma Cell Line to Antitumor Drugs

Studies of Proton Pump Inhibitors and Tumor Resistance to Antitumor Drugs

Effects of Proton Pump Inhibitors on Gastric Cancer Cells and Their Mechanisms of Action

Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo.

effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-aTPases/Pi3K/akt/mTOr/hiF-1 α signaling pathway through Tsc1/2 complex and rheb in human gastric adenocarcinoma cells in vitro and in vivo

The Proton Pump Inhibitor Pantoprazole Disrupts Protein Degradation Systems and Sensitizes Cancer Cells to Death under Various Stresses

Tumor Microenvironment Interruption: a Novel Anti-Cancer Mechanism of Proton-pump Inhibitor in Gastric Cancer by Suppressing the Release of Microrna-Carrying Exosomes.

Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition.

Proton Pump Inhibitor Pantoprazole Abrogates Adriamycin-Resistant Gastric Cancer Cell Invasiveness Via Suppression of Akt/GSK-β/β-catenin Signaling and Epithelial–mesenchymal Transition

Synergistic Effects of Proton Pump Inhibitors and Chemotherapy Drugs

Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells

Effects of Polyphyllin I on Growth Inhibition of Human Non-Small Lung Cancer Cells and in Xenograft

Repositioning of Proton Pump Inhibitors in Cancer Therapy

Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo.

Effect Of Pantoprazole On Human Gastric Adenocarcinoma Sgc7901 Cells Through Regulation Of Phospho-Lrp6 Expression In Wnt/Beta-Catenin Signaling

Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines.

Proton pump inhibitors stabilize the expression of PD‐L1 on cell membrane depending on the phosphorylation of GSK3β

Proton Pump Inhibitors Display Anti‐tumour Potential in Glioma

Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer.

Pantoprazole Augments Sensitivity of Human Gastric Adenocarcinoma Cells to Cisplatin by Inhibition of Autophagy